Phase I/II Study to Determine the Safety, Tolerability, Biological Activity and Efficacy of Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19(UCART019) in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Phase I/II Study to Determine the Safety, Tolerability, Biological Activity and Efficacy of Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19(UCART019) in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in B Cell Leukemia, B Cell Lymphoma. SEO and diligence focus: UCART019, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: B Cell Leukemia
Modality: protein therapy
Target: UCART019
Sponsor: Chinese PLA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: UCART019
View original source fields
Condition raw: B Cell Leukemia, B Cell Lymphoma
Condition normalized: B Cell Leukemia, B Cell Lymphoma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: UCART019
Target normalized: UCART019